Classification according to the EANO-ESMO guidelines adds prognostic value to the diagnosis of patients with leptomeningeal metastases (LM), a study has shown.
“LM affects 10% of patients with metastatic solid tumors, and median overall survival (OS) is about 2 to 6 months” said Dr Emilie Le Rhun of Zurich University Hospital in Zurich, Switzerland.
The EANO-ESMO (European Association of Neuro-Oncology and European Society for Medical Oncology) classification system is based on: